Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price

[Business Wire] – MELA Sciences, Inc. , developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDA more

View todays social media effects on MELA

View the latest stocks trending across Twitter. Click to view dashboard

See who MELA is hiring next, click here to view